NCT07169617 2026-03-18
Testing the SurVaxM Vaccine for Lung Cancer Prevention
National Cancer Institute (NCI)
Phase 2 Not yet recruiting
Clinical Trials
25 trialsNCT07078604 2026-03-12
A Cancer Vaccine (STEMVAC) in Combination With Chemotherapy for the Treatment of PD-L1 Negative Metastatic Triple-Negative Breast Cancer
University of Washington
Phase 2 Recruiting
NCT02455557 2026-02-25
SurVaxM Vaccine Therapy and Temozolomide in Treating Patients With Newly Diagnosed Glioblastoma
Roswell Park Cancer Institute
Phase 2 Active not recruiting
NCT03794349 2026-02-18
Irinotecan Hydrochloride, Temozolomide, and Dinutuximab With or Without Eflornithine in Treating Patients With Relapsed or Refractory Neuroblastoma
Children's Oncology Group
Phase 2 Active not recruiting
NCT05455658 2025-10-24
STEMVAC in Patients With Early Stage Triple Negative Breast Cancer
University of Washington
Phase 2 Active not recruiting
NCT03786783 2025-10-09
Dinutuximab, Sargramostim, and Combination Chemotherapy in Treating Patients With Newly Diagnosed High-Risk Neuroblastoma
National Cancer Institute (NCI)
Phase 2 Active not recruiting
NCT06013618 2025-06-17
Clinical Analysis of Naxitamab (hu3F8) in the Treatment of Pediatric High Risk or Refractory/ Relapsed Neuroblastoma
Sun Yat-sen University
Phase 2 Recruiting
NCT02728102 2024-05-07
Dendritic Cell/Myeloma Fusion Vaccine for Multiple Myeloma (BMT CTN 1401)
National Heart, Lung, and Blood Institute (NHLBI)
Phase 2 Completed
NCT04197687 2023-12-18
TPIV100 and Sargramostim for the Treatment of HER2 Positive, Stage II-III Breast Cancer in Patients With Residual Disease After Chemotherapy and Surgery
Academic and Community Cancer Research United
Phase 2 Unknown
NCT02636582 2023-12-05
Nelipepimut-S Plus GM-CSF Vaccine Therapy in Treating Patients With Breast Cancer
National Cancer Institute (NCI)
Phase 2 Completed
NCT05344209 2023-11-09
LUNGVAC
Vestre Viken Hospital Trust
Phase 2 Recruiting
NCT02484443 2023-10-26
Dinutuximab in Combination With Sargramostim in Treating Patients With Recurrent Osteosarcoma
National Cancer Institute (NCI)
Phase 2 Completed
NCT01767194 2022-10-24
Irinotecan Hydrochloride and Temozolomide With Temsirolimus or Dinutuximab in Treating Younger Patients With Refractory or Relapsed Neuroblastoma
National Cancer Institute (NCI)
Phase 2 Completed
NCT00488592 2021-07-12
Peptide Vaccinations to Treat Patients With Low-Risk Myeloid Cancers
National Institutes of Health Clinical Center (CC)
Phase 2 Completed
NCT02677155 2021-03-01
Lymvac-2
Oslo University Hospital
Phase 2 Completed
NCT01363206 2020-03-19
GIPI
Northern California Melanoma Center
Phase 2 Completed
NCT00514215 2020-03-05
Cryotherapy and GM-CSF in Treating Patients With Lung Metastases or Primary Lung Cancer
Barbara Ann Karmanos Cancer Institute
Phase 2 Completed
NCT00274287 2019-03-28
GM-CSF for Maintenance of Prostate Cancer for Patients Responding to Taxotere
Oncology Specialists, S.C.
Phase 2 Completed
NCT00481832 2018-02-14
Autologous Followed by Non-myeloablative Allogeneic Transplantation for Non-Hodgkin's Lymphoma
Stanford University
Phase 2 Terminated
NCT00477087 2017-11-29
Phase II GM-CSF Plus Mitoxantrone in Hormone Refractory Prostate Cancer
Stanford University
Phase 2 Terminated
NCT01939730 2015-11-04
Rituximab + GM-CSF in Patients With Follicular B-Cell Lymphoma
M.D. Anderson Cancer Center
Phase 2 Completed
NCT00066365 2015-03-30
Inhaled Sargramostim in Treating Patients With First Pulmonary (Lung) Recurrence of Osteosarcoma
Children's Oncology Group
Phase 2 Completed
NCT00002594 2014-07-24
Combination Chemotherapy Followed by Bone Marrow and/or Peripheral Stem Cell Transplantation in Treating Patients With Recurrent Medulloblastoma or CNS Germ Cell Tumors
Children's Oncology Group
Phase 2 Completed
NCT00505921 2011-11-16
Autologous and Allogenic Transplantation With Campath-1H for T-Cell Lymphoma
M.D. Anderson Cancer Center
Phase 2 Terminated
NCT00001237 2008-03-04
Pilot Protocol for the Treatment of Patients With Small Non-Cleaved and Diffuse Large Cell Lymphomas
National Institutes of Health Clinical Center (CC)
Phase 2 Completed